Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study

dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorÖzbalak, Murat
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorYıldız, Birol
dc.contributor.authorUzay, Ant
dc.contributor.authorYiğenoğlu, Tuğçe Nur
dc.contributor.authorElverdi, Tuğrul
dc.contributor.authorAyyıldız, Orhan
dc.contributor.orcid0000-0002-6759-1939
dc.contributor.orcid0000-0002-3040-4052
dc.contributor.orcid0000-0002-6692-085X
dc.contributor.orcid0000-0003-1381-4188
dc.contributor.orcid0000-0001-9962-8882
dc.contributor.orcid0000-0001-5673-8408
dc.date.accessioned2024-04-24T15:59:24Z
dc.date.available2024-04-24T15:59:24Z
dc.date.issued2021
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractThe AETHERA trial reported an increased progression-free survival (PFS) when brentuximab vedotin (BV) was used as maintenance therapy in high-risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). Thus, we aimed to determine the impact and safety of BV as maintenance after ASCT in real-world patients. Seventy-five patients with relapsed/refractory HL started on BV consolidation therapy after ASCT due to high risk of relapse, between January 2016 and July 2019, from 25 institutions, were included in the study. The median follow-up time was 26 months. The most common high-risk features were primary refractory or relapsed disease <12 months (n = 61), lack of complete response (CR) to the last salvage regimen (n = 51), and having had at least two salvage regimens (n = 29). At the time of analysis, 42 patients completed consolidation courses, and BV was discontinued in 33 patients. Fifty patients had an ongoing response (CR in 41, PR in 6, and SD in 3 patients), 25 had progressed. Ten died in the follow-up, eight with progressive disease and two due to infection while in CR. The 2-year PFS and OS rates were 67.75% (95% confidence interval [CI]: 0.55-0.77) and 87.61% (95% CI: 0.76-0.94), respectively. Seventeen patients (23%) received BV in the pre-ASCT treatment lines, and there was no survival difference between the BV-naive and BV-exposed groups. The most common adverse events were neutropenia (27%) and peripheral neuropathy (21%). Sixteen patients (21.3%) experienced grade 3 or 4 toxicity. BV was discontinued due to adverse event in 12 patients. Consolidation with BV after ASCT can achieve a 2-year PFS of 67.75% (95% CI: 0.55-0.75) with an acceptable toxicity profile.en_US
dc.identifier.citationAkay, O. M., Özbalak, M., Pehlivan, M., Yıldız, B., Uzay, A., Yiğenoğlu, T. N. ve diğerleri. (2021). Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. Hematological Oncology, 39(4), 498-505.
dc.identifier.doi10.1002/hon.2897
dc.identifier.endpage505en_US
dc.identifier.issn0278-0232
dc.identifier.issn1099-1069
dc.identifier.issue4en_US
dc.identifier.pmid34171130
dc.identifier.scopus2-s2.0-85108832322
dc.identifier.scopusqualityQ2
dc.identifier.startpage498en_US
dc.identifier.urihttps://doi.org/10.1002/hon.2897
dc.identifier.urihttps://hdl.handle.net/11468/14044
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/hon.2897
dc.identifier.volume39en_US
dc.identifier.wosWOS:000668225700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAyyıldız, Orhan
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofHematological Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutologous stem cell transplantationen_US
dc.subjectBrentuximab vedotinen_US
dc.subjectConsolidationen_US
dc.subjectHodgkin lymphomaen_US
dc.subjectRelapsed and refractoryen_US
dc.titleBrentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective studyen_US
dc.titleBrentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma.pdf
Boyut:
567.9 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası